A World Without Infectious Disease
A new era
We are developing a broad portfolio of product candidates that are designed to combat serious, global infectious diseases in entirely new ways, creating medicines that will have a meaningful impact on people around the world.
Given the global impact of infectious diseases, we are committed to developing cost-effective treatments that can be delivered at scale.
HBV
VIR-2218 + PEG-IFN-⍺
(Treatment)
- Indication:
- siRNA
- Phase:
- Phase 2,66%†
- Collaboration:
- Alnylam
VIR-3434 ± VIR-2218 ± PEG-IFN-⍺1
(Treatment)
- Indication:
- siRNA/Antibody
- Phase:
- Phase 2,66%†
- Collaboration:
- Alnylam
VIR-2218 + BRII-179
(Treatment)
- Indication:
- siRNA
- Phase:
- Phase 2,66%
- Collaboration:
- Alnylam / Brii Bio
VIR-2218 + TLR82 + PD-13
(Treatment)
- Indication:
- siRNA
- Phase:
- Phase 2,66%
- Collaboration:
- Alnylam / Gilead
HDV
VIR-2218 + VIR-3434
(Treatment)
- Indication:
- siRNA/Antibody
- Phase:
- Phase 2,66%
- Collaboration:
- Alnylam
Influenza A
VIR-2482
(Prophylaxis)
- Indication:
- Antibody
- Phase:
- Phase 2,66%
- Collaboration:
COVID-19
Sotrovimab
(Treatment – Early)
- Indication:
- Antibody
- Phase:
- Authorized,66%
- Collaboration:
- GlaxoSmithKline
Sotrovimab
(Treatment – Hospitalized)
- Indication:
- Antibody
- Phase:
- Phase 3,50%
- Collaboration:
- GlaxoSmithKline
Sotrovimab
(Prophylaxis)
- Indication:
- Antibody
- Phase:
- Phase 3,50%
- Collaboration:
- GlaxoSmithKline
HIV
VIR-1111*
(Prophylaxis)
- Indication:
- T Cell
- Phase:
- Phase 1,66%
- Collaboration:
- Bill and Melinda Gates Foundation
VIR-1388
(Prophylaxis)
- Indication:
- T Cell
- Phase:
- Pre-clinical,66%
- Collaboration:
- Bill and Melinda Gates Foundation
1: MARCH trial (Part B), PREVAIL platform trial (THRIVE/STRIVE sub-protocols)
2: GS-9688
3: nivolumab
†: sotrovimab for early treatment by IV currently has marketing approval, temporary authorization or emergency use authorization in >40 countries. In April 2022, the FDA deauthorized sotrovimab‘s use in all US regions.
*Vaccine designed to establish proof of concept in Phase (Ph) 1 clinical trial to determine whether unique immune response observed in non-human primates can be replicated in humans; ultimately, any candidates we advance as a potential HIV vaccine will require modifications to VIR-1111 before further clinical development.
Our Focus
Chronic and acute infections impact hundreds of millions of people every year.
We are taking aim at some of the world’s largest and most serious infectious diseases, infections that are evasive, challenging, or insufficiently addressed by current approaches including COVID-19, hepatitis B and hepatitis D, influenza A and HIV.
HIV
Each year, there are approximately 1.8 million new cases globally of human immunodeficiency virus (HIV) and approximately 1.0 million HIV-related deaths. Highly effective treatments have fundamentally changed the course of the disease; however, current prevention approaches and medicines have had only a modest effect on HIV transmission in high-risk populations. We believe the most effective means of curbing the worldwide HIV epidemic would be a safe and effective vaccine.
HBV
Approximately 290 million people globally are chronically infected with hepatitis B virus (HBV) and approximately 900,000 of them die from HBV-associated complications each year. Currently, a year-long course of pegylated interferon-alpha is the best available curative therapy and it has a low functional cure rate of approximately 3-7%. Alternatively, suppressive therapy with nucleotide/nucleoside reverse transcriptase inhibitors is commonly used, but patients often require a lifetime of therapy. There is a significant unmet need for effective therapies that lead to life-long control of the virus after a finite duration of therapy, which is the definition of a functional cure.
Flu
On average, the influenza virus infects 5-10% of the world’s population annually and results in an estimated 500,000 deaths. The efficacy of the flu vaccine ranges each year with an average of 40%. This is because flu vaccines often do not provide protection against all strains of influenza that circulate in a given season and many people who receive the vaccine do not produce an effective immune response. A universal flu prophylactic that could overcome both of these limitations and be used year after year would be transformative.
SARS-CoV-2
The substantial impact of viral outbreaks and the lack of global preparedness have been highlighted by the current coronavirus disease 2019, or COVID-19, pandemic. The vast number of recorded infections, deaths and countries impacted is unlike anything we have witnessed in the past century. It is becoming increasingly clear that multiple therapeutic approaches that target SARS-CoV-2, the virus that causes COVID-19, may be necessary to stop this disease. Evidence also suggests that there will be likely future coronavirus outbreaks that will require safe and effective interventions – treatments and vaccines – that can work against multiple different viral strains.
TB
Tuberculosis (TB) is the leading cause of death from a single infectious agent globally. Each year, there are approximately 10 million new cases of TB and 1.6 million deaths. Approximately 1.7 billion people are estimated to have an asymptomatic form of TB, known as latent TB. The bacteria that causes TB is not easily cleared by boosting our immune system’s natural response to infection, which may be one reason why an effective TB vaccine does not yet exist. A safe and effective vaccine that prevents active pulmonary TB has the potential to help curb this worldwide epidemic.
